Clinical Trial Update: Pembrolizumab After SBRT Versus Pembrolizumab Alone in Advanced NSCLC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial comparing pembrolizumab after SBRT versus pembrolizumab alone in advanced non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED